CY1105992T1 - Σ-μεθυλ-διυδρο-ζιπρασιδονη για τη θepαπευτικη αγωγη ψυχιατρικων διαταραχων - Google Patents

Σ-μεθυλ-διυδρο-ζιπρασιδονη για τη θepαπευτικη αγωγη ψυχιατρικων διαταραχων

Info

Publication number
CY1105992T1
CY1105992T1 CY20071100161T CY071100161T CY1105992T1 CY 1105992 T1 CY1105992 T1 CY 1105992T1 CY 20071100161 T CY20071100161 T CY 20071100161T CY 071100161 T CY071100161 T CY 071100161T CY 1105992 T1 CY1105992 T1 CY 1105992T1
Authority
CY
Cyprus
Prior art keywords
disorder
disorders
anxiety
treatment
psychotic
Prior art date
Application number
CY20071100161T
Other languages
English (en)
Inventor
Chandra Prakash
Teresa Annette Smolarek
Original Assignee
Pfizer Products Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105992(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated
Publication of CY1105992T1 publication Critical patent/CY1105992T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε φαρμακευτικές συνθέσεις περιέχουσες S-μεθυλ-διυδρο-ζιπρασιδόνη και στη χρήση μιας τέτοιας ένωσης και των φαρμακευτικώς αποδεκτών αλάτων αυτής για τη θεραπευτική αγωγή ψυχιατρικών διαταραχών. Ειδικότερα, αναφέρεται στη χρήση μιας τέτοιας ένωσης και των φαρμακευτικώς αποδεκτών αλάτων αυτής για τη θεραπευτική αγωγή μιας διαταραχής ή κατάστασης που επιλέγεται από: σχιζοφρένεια, διαταραχές άγχους όπως διαταραχή γενικευμένου άγχους, διαταραχή πανικού, διαταραχή μετατραυματικού στρες και φοβίες (π.χ., κοινωνική φοβία, αγοραφοβία κ.λ.π)˙ ψυχωτικά επεισόδια άγχους: άγχος, ταραχή, υπέρμετρη επιθετικότητα, ένταση, ή κοινωνική ή συναισθηματική απόσυρση συνδεόμενη με ψύχωση· διαταραχή της διάθεσης με ψυχωτικά στοιχεία όπως δριμεία μείζονα καταθλιπτική διαταραχή· διαταραχές της διάθεσης συνδεόμενες με ψυχωτικές διαταραχές όπως οξεία μανία και κατάθλιψη συνδεόμενη με διπολική διαταραχή, και διαταραχές της διάθεσης συνδεόμενες με σχιζοφρένεια· συμπεριφορικές διαταραχές συνδεόμενες με νοητική υστέρηση, αυτιστική διαταραχή, και διαταραχή επαφής· άνοιες όπως άνοιες συνδεόμενες με νόσο του Alzheimer˙ προκαλούμενες από φάρμακο και βασιζόμενες σε νευροεκφυλισμό δυσκινησίες· ψυχαναγκαστική καταναγκαστική διαταραχή· και σύνδρομο του Tourette.
CY20071100161T 2000-06-02 2007-02-08 Σ-μεθυλ-διυδρο-ζιπρασιδονη για τη θepαπευτικη αγωγη ψυχιατρικων διαταραχων CY1105992T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16
EP01932011A EP1286672B1 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for the treatment of ocular disorders.

Publications (1)

Publication Number Publication Date
CY1105992T1 true CY1105992T1 (el) 2011-04-06

Family

ID=26903852

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100161T CY1105992T1 (el) 2000-06-02 2007-02-08 Σ-μεθυλ-διυδρο-ζιπρασιδονη για τη θepαπευτικη αγωγη ψυχιατρικων διαταραχων

Country Status (44)

Country Link
US (1) US20060287336A1 (el)
EP (3) EP1698338B1 (el)
JP (2) JP2003534381A (el)
KR (1) KR20030007824A (el)
CN (1) CN1431901A (el)
AP (2) AP1831A (el)
AR (1) AR028937A1 (el)
AT (3) ATE345818T1 (el)
AU (1) AU2001258690A1 (el)
BG (1) BG107267A (el)
BR (1) BR0111271A (el)
CA (1) CA2410618A1 (el)
CY (1) CY1105992T1 (el)
CZ (1) CZ20023860A3 (el)
DE (3) DE60124791T2 (el)
DK (1) DK1468686T3 (el)
DO (1) DOP2001000181A (el)
EA (1) EA007068B1 (el)
EC (1) ECSP024369A (el)
EE (1) EE200200670A (el)
ES (1) ES2277170T3 (el)
GE (1) GEP20053512B (el)
HN (1) HN2001000119A (el)
HR (1) HRP20020953A2 (el)
HU (1) HUP0301747A2 (el)
IL (2) IL152782A0 (el)
IS (1) IS6619A (el)
MA (1) MA26908A1 (el)
MX (1) MXPA02011862A (el)
NO (1) NO325077B1 (el)
NZ (1) NZ551012A (el)
OA (1) OA12267A (el)
PA (1) PA8518301A1 (el)
PE (1) PE20011329A1 (el)
PL (1) PL365576A1 (el)
PT (2) PT1698338E (el)
SI (1) SI1468686T1 (el)
SK (1) SK16622002A3 (el)
SV (1) SV2002000473A (el)
UA (1) UA79425C2 (el)
UY (1) UY26742A1 (el)
WO (1) WO2001091756A2 (el)
YU (1) YU90702A (el)
ZA (1) ZA200209665B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054487A2 (en) 2002-12-13 2004-07-01 Regents Of The University Of Minnesota Scleral depressor
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126590A (en) * 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP0985414B1 (en) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
JP2002541098A (ja) * 1999-04-06 2002-12-03 セプラコア インコーポレーテッド ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物

Also Published As

Publication number Publication date
PT1468686E (pt) 2007-01-31
JP2003534381A (ja) 2003-11-18
IL152782A0 (en) 2003-06-24
EP1468686B1 (en) 2006-11-22
UA79425C2 (en) 2007-06-25
SK16622002A3 (sk) 2004-07-07
ATE391507T1 (de) 2008-04-15
KR20030007824A (ko) 2003-01-23
ES2277170T3 (es) 2007-07-01
CA2410618A1 (en) 2001-12-06
YU90702A (sh) 2005-11-28
GEP20053512B (en) 2005-05-10
HRP20020953A2 (en) 2005-02-28
NO20025760L (no) 2003-01-15
AR028937A1 (es) 2003-05-28
IL152782A (en) 2007-10-31
US20060287336A1 (en) 2006-12-21
DE60133596D1 (de) 2008-05-21
EA200201168A1 (ru) 2003-06-26
IS6619A (is) 2002-11-14
NZ551012A (en) 2008-04-30
WO2001091756A2 (en) 2001-12-06
PL365576A1 (en) 2005-01-10
HN2001000119A (es) 2001-09-11
PE20011329A1 (es) 2002-01-15
ZA200209665B (en) 2003-11-28
BR0111271A (pt) 2003-06-10
DE60124093D1 (de) 2006-12-07
ECSP024369A (es) 2003-02-06
CZ20023860A3 (cs) 2004-01-14
AP2005003272A0 (en) 2005-03-31
ATE345818T1 (de) 2006-12-15
EP1286672A2 (en) 2003-03-05
BG107267A (bg) 2003-06-30
OA12267A (en) 2004-01-20
EE200200670A (et) 2004-08-16
EP1698338B1 (en) 2008-04-09
MA26908A1 (fr) 2004-12-20
DE60124791T2 (de) 2007-09-13
AP1831A (en) 2008-02-26
SI1468686T1 (sl) 2007-04-30
EP1698338A3 (en) 2006-09-20
EP1468686A2 (en) 2004-10-20
PT1698338E (pt) 2008-06-03
MXPA02011862A (es) 2003-04-10
EP1698338A2 (en) 2006-09-06
CN1431901A (zh) 2003-07-23
PA8518301A1 (es) 2002-09-17
WO2001091756A3 (en) 2002-09-26
JP2008056700A (ja) 2008-03-13
UY26742A1 (es) 2001-12-28
EP1468686A3 (en) 2004-12-01
DE60124791D1 (de) 2007-01-04
NO325077B1 (no) 2008-01-28
EP1286672B1 (en) 2006-10-25
SV2002000473A (es) 2002-10-24
EA007068B1 (ru) 2006-06-30
DOP2001000181A (es) 2002-04-15
DK1468686T3 (da) 2007-03-12
ATE343387T1 (de) 2006-11-15
NO20025760D0 (no) 2002-11-29
AU2001258690A1 (en) 2001-12-11
AP1747A (en) 2007-05-31
HUP0301747A2 (hu) 2003-09-29

Similar Documents

Publication Publication Date Title
CY1105992T1 (el) Σ-μεθυλ-διυδρο-ζιπρασιδονη για τη θepαπευτικη αγωγη ψυχιατρικων διαταραχων
CY1118363T1 (el) Αντισωματα που ανοσοειδικως συνδεονται προς blys
GT200100183A (es) Derivados de quinolina y quinazolina.
EA200400498A1 (ru) Производные фенилпиперазина как ингибиторы обратного захвата серотонина
BR0106717A (pt) Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CA2256227A1 (en) Method of treating psychiatric conditions
BR9914293A (pt) Processo para a purificação de 1,3-propanodiol
BR0215182A (pt) Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
ATE546586T1 (de) Verbesserte krepphilfsmittel modifizierer und verfahren zur herstellung von papierprodukten
EA201000714A1 (ru) Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета амилоидного пептида
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
BR0116332A (pt) Processo para o aumento da estabilidade
CY1109729T1 (el) Τερφαινυλ παραγωγα για θεραπεια της νοσου του alzheimer
JP2005523335A5 (el)
MXPA05012391A (es) Tratamiento de trastornos psicoticos y depresivos.
AR028705A1 (es) Bis-arilsulfonas
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
ID29715A (id) Hidrogenasi berlanjut senyawa aromatik ternitrasi menggunakan katalis berkadar alumunium rendah
Post et al. Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
DE60025639D1 (de) Substituierte diazepan
ATE552251T1 (de) Thiophen- und furanverbindungen
BR0207186A (pt) Composição para alvejamento pelo ar, e, processo para a preparação da mesma
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos